Search Press releases Keywords From To 31 May 2024 Acquisition of own shares Read More 31 May 2024 UCB announces positive CHMP opinion for 320 mg device presentations of BIMZELX[®]▼ (bimekizumab) Read More 24 May 2024 Acquisition of own shares Read More 23 May 2024 UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa Read More 17 May 2024 Transparency notification Wellington Read More 17 May 2024 Acquisition of own shares Read More Pagination First page Previous page Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
